Full Press Release Details
FLORHAM PARK, N.J., March 30, 2026 (GLOBE NEWSWIRE) --BeyondSpring Inc.(NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced that the Company will have a poster presentation at the2026 Annual Meeting of the American Association for Cancer Research ("AACR"), taking place on April 17 through 22, 2026 in San Diego, California.
Presentation Details:
• Title:Plinabulin Boosts Antitumor Efficacy of Topoisomerase Inhibitor-based Antibody-drug Conjugates Without or With Immune Checkpoint Inhibitor
• Presenter / Authors:Yingjuan June Lu, Xiaoyan He, Weiwei Cheng, Zhengyan Zhang, James Tonra,Lan Huang
• Presentation Time:April 21, 2026, 2PM to 5PM PT
• Location:Poster Section 8 at San Diego Convention Center
• Session Category:Immunology
• Session Title:T Cell Engagers 2 / Antibody-Drug Conjugates 1
• Poster Board Number:16
• Poster Number:5597
About BeyondSpringBeyondSpring (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company developing first-in-class therapies addressing high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in NSCLC and other indications. Plinabulin’s novel mechanism as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering a unique approach to restoring tumor sensitivity to checkpoint inhibitors. Learn more at https://beyondspringpharma.com.